Behrad Derakhshan
Corporate Officer/Principal bij EDGEWISE THERAPEUTICS, INC.
Vermogen: 213 947 $ op 30-04-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Kevin Koch | M | 63 | 7 jaar | |
| Peter Thompson | M | 64 | 7 jaar | |
| Alan Russell | M | 54 | 7 jaar | |
| Badreddin Edris | M | 37 | 7 jaar | |
| Jon Root | M | 64 | 5 jaar | |
| Elvire Gouze | M | - |
Innoskel SASU
 Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | - |
| Laura Brege | F | 66 | 4 jaar | |
| Jonathan Fox | M | 66 | 1 jaar | |
| Rajul Jain | M | - |
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | - |
| Rachel Maers | F | - |
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | - |
| Marc Semigran | M | 67 | 2 jaar | |
| Michel Detheux | M | 57 |
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | 2 jaar |
| John Moore | M | 59 | 4 jaar | |
| Leslie Leinwand | M | - | - | |
| Joanne Donovan | M | 67 | 3 jaar | |
| R. Carruthers | M | 66 | 4 jaar | |
| Piyush Sharma | M | - | 7 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| David Hallal | M | 57 | 10 jaar | |
| Stephen P. Squinto | M | 67 | 23 jaar | |
| Felix Baker | M | 55 | 6 jaar | |
| Ludwig Hantson | M | 61 | 4 jaar | |
| Kenneth Harrison | M | 44 | 4 jaar | |
| Tina Beamon | F | - | 3 jaar | |
| Mark Day | M | 52 | 2 jaar | |
| Rana Strellis | F | - | 4 jaar | |
| William Keller | M | 75 | 6 jaar | |
| Richard Porter | M | - |
Therachon AG
| 3 jaar |
| George Llado | M | 58 | - | |
| Micah Zajic | M | 43 | 3 jaar | |
| Lisa Trivison Beck | F | 62 | 3 jaar | |
| Thomas-Christian Mix | M | 57 | 2 jaar | |
| Martine Zimmermann | M | 55 | 7 jaar | |
| Aled Williams | M | - |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 1 jaar |
| Richard Riese | M | 61 | 3 jaar | |
| Jens Renstrup | M | 59 | 3 jaar | |
| Brian Krex | M | 57 | 4 jaar | |
| Randy Teel | M | 45 | 2 jaar | |
| Massimiliano Colao | M | 59 | 3 jaar | |
| Melissa Manno | F | - | 2 jaar | |
| Jeffrey Fryer | M | 55 | 9 jaar | |
| Mohammed Qatanani | M | 50 | 3 jaar | |
| James Engelhart | M | 60 | 2 jaar | |
| Jason Meyenburg | M | 47 | 13 jaar | |
| Saqib Islam | M | 54 | 3 jaar | |
| Dominique Monnet | M | 65 | 1 jaar | |
| Henric Bjarke | M | 57 | 5 jaar | |
| Dave Anderson | M | 74 | 1 jaar | |
| Stephanie Fagan | F | - | 2 jaar | |
| Paresh N. Soni | M | 63 | 2 jaar | |
| Bill Lundberg | M | 60 | 4 jaar | |
| Jeremy Springhorn | M | 61 | 9 jaar | |
| Jeroen van Beek | M | - | 10 jaar | |
| John Tilton | M | 56 | 10 jaar | |
| Jing Marantz | M | 58 | 2 jaar | |
| Julie O'Neill | F | 58 | 3 jaar | |
| Mittie Doyle | M | 59 | 3 jaar | |
| Radhika Tripuraneni | M | 44 | - | |
| Al Boyle | M | - | 6 jaar | |
| Derek Adams | M | 50 | 11 jaar | |
| Joseph Newell | M | 54 | 2 jaar | |
| Vikas Sinha | M | 60 | 11 jaar | |
| Julie VanOrsdel Daves | F | - | 3 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 56 | 90.32% |
| Frankrijk | 4 | 6.45% |
| Zwitserland | 2 | 3.23% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Behrad Derakhshan
- Persoonlijk netwerk
